Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to less than 18 Years of Age, Hospitalized With Acute Heart Failure
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Serelaxin (Primary)
- Indications Acute heart failure
- Focus Adverse reactions; Pharmacokinetics
- Acronyms RELAX-PEDS-PK
- Sponsors Novartis Pharmaceuticals Corporation
- 22 May 2017 Status changed from recruiting to discontinued.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2017 to 13 Apr 2018.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.